(R)-Roscovitine
Based on 35 publication(s) in Google Scholar
(R)-Roscovitine (Seliciclib) is an orally bioavailable, selective and BBB-permeable CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.
For research use only. We do not sell to patients.
- Purity: 99.53%
- CAS No.: 186692-46-6
- Formula: C19H26N6O
- Molecular Weight:354.45
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) (R)-Roscovitine
More- Nature. 2020 Sep;585(7824):293-297. [Abstract]
- Nat Cell Biol. 2024 Oct;26(10):1773-1789. [Abstract]
- Nat Commun. 2025 Mar 4;16(1):2174. [Abstract]
- Nat Commun. 2024 Oct 1;15(1):8481. [Abstract]
- Cell Death Differ. 2021 Jan;28(1):337-348. [Abstract]
- Transl Neurodegener. 2024 Aug 2;13(1):39. [Abstract]
- Acta Pharm Sin B. 2023 Sep;13(9):3708-3727. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Small. 2024 Jun 10:e2311507. [Abstract]
- Redox Biol. 2022 Sep:55:102418. [Abstract]
- Clin Cancer Res. 2024 Sep 13;30(18):4179-4189. [Abstract]
- EMBO Mol Med. 2024 Oct;16(10):2402-2426. [Abstract]
- Cell Syst. 2018 Apr 25;6(4):424-443.e7. [Abstract]
- Neoplasia. 2018 Mar 28;20(5):478-488. [Abstract]
- Oncogene. 2026 Jun 10. [Abstract]
- Cell Rep. 2021 Jul 20;36(3):109394. [Abstract]
- Br J Cancer. 2023 Mar;128(7):1344-1359. [Abstract]
- J Med Chem. 2021 Mar 11;64(5):2725-2738. [Abstract]
- J Pineal Res. 2025 Jul;77(4):e70063. [Abstract]
- Eur J Pharmacol. 2022 Aug 15:929:175118. [Abstract]
- Mol Cancer Res. 2020 Jan;18(1):91-104. [Abstract]
- J Biol Chem. 2023 Apr;299(4):103059. [Abstract]
- Oncol Rep. 2020 Jan;43(1):306-317. [Abstract]
- J Virol. 2023 Jun 29;97(6):e0037023. [Abstract]
- Brain Res Bull. 2023 Dec:205:110822. [Abstract]
- Biochimie. 2020 Jan;168:277-284. [Abstract]
- Virology. 2021 Aug:560:96-109. [Abstract]
- Chin J Org Chem. 2017, 37 (6): 1479-1486.
- Chin J Org Chem. 2016, 36(5): 1044-1050.
- Neuroreport. 2018 Mar 7;29(4):241-246. [Abstract]
- Seoul National University. 2025.
- bioRxiv. 2024 Nov 4:2024.10.08.617155. [Abstract]
- bioRxiv. 2024 September 22.
- Harvard University. 2023 Mar. 30487357.
- University of Rijeka. 2023.
-
Flow Cytometry
-
WB
-
Cell Imaging/Staining
-
WB
-
WB
Biological Activity
|
cdc2/cyclin B 0.65 μM (IC50) |
cdk2/cyclin A 0.7 μM (IC50) |
Cdk2/cyclin E2 0.7 μM (IC50) |
CDK5/p35 0.16 μM (IC50) |
GST-erk1 30 μM (IC50) |
erk1 34 μM (IC50) |
erk2 14 μM (IC50) |
IR tyrosine kinase 70 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 786-0 | GI50 |
25.1 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human 786-0 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human 786-0 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| A2780 | GI50 |
12.5 μM
Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine
|
Growth inhibition of cisplatin-resistant human A2780 cells after 96 hrs by sulforhodamine B assay
Growth inhibition of cisplatin-resistant human A2780 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 21982796] |
| A2780 | GI50 |
4.45 μM
Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine
|
Growth inhibition of cisplatin-susceptible human A2780 cells after 96 hrs by sulforhodamine B assay
Growth inhibition of cisplatin-susceptible human A2780 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 21982796] |
| A-375 | IC50 |
11.79 μM
Compound: Roscovitine
|
Antiproliferative activity against human A-375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human A-375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 32361064] |
| A498 | GI50 |
50.1 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human A498 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human A498 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| A498 | IC50 |
13.2 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 wild-type human A498 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 wild-type human A498 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| A549 | GI50 |
12.6 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human A549 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human A549 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| A549 | GI50 |
15 μM
Compound: Roscovitine
|
Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21080703] |
| A549 | IC50 |
>10 μM
Compound: Roscovitine
|
Antiproliferative activity against human A549 cells measured after 72 hrs by CCK8 assay
Antiproliferative activity against human A549 cells measured after 72 hrs by CCK8 assay
|
[PMID: 31272794] |
| A549 | IC50 |
>100 μM
Compound: Roscovitine
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| A549 | IC50 |
14.14 μM
Compound: (R)-roscovitine
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 23036956] |
| A549 | IC50 |
14.7 μM
Compound: Roscovitine
|
Antiproliferative activity against human A549 cells after 3 days by SRB assay
Antiproliferative activity against human A549 cells after 3 days by SRB assay
|
[PMID: 20361800] |
| A549 | IC50 |
15.9 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 wild-type human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 wild-type human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| A549 | IC50 |
2.18 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 23623491] |
| ACHN | GI50 |
12.6 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human ACHN cells after 72 hrs by ViaLight assay
Antiproliferative activity against human ACHN cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| ACHN | IC50 |
11.9 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 wild-type human ACHN cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 wild-type human ACHN cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| ACHN | IC50 |
2.88 μM
Compound: 1
|
Cytotoxicity against human ACHN cells after 48 hrs by MTT assay
Cytotoxicity against human ACHN cells after 48 hrs by MTT assay
|
[PMID: 23623491] |
| AN3-CA | IC50 |
14.1 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against human AN3-CA cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against human AN3-CA cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| ASPC1 | IC50 |
17767 nM
Compound: Roscovitine
|
Antiproliferative activity against human AsPC1 cells after 72 hrs by prestoblue assay
Antiproliferative activity against human AsPC1 cells after 72 hrs by prestoblue assay
|
[PMID: 30343954] |
| BXPC-3 | IC50 |
15284 nM
Compound: Roscovitine
|
Antiproliferative activity against human BxPC3 cells after 72 hrs by prestoblue assay
Antiproliferative activity against human BxPC3 cells after 72 hrs by prestoblue assay
|
[PMID: 30343954] |
| Caco-2 | IC50 |
10 μM
Compound: Roscovitin
|
Cytotoxicity against human Caco2 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis
Cytotoxicity against human Caco2 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis
|
[PMID: 21944287] |
| Caco-2 | IC50 |
10 μM
Compound: Roscovitine
|
Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| Caco-2 | IC50 |
12.9 μM
Compound: Rosco
|
Cytotoxicity against human Caco2 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
Cytotoxicity against human Caco2 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
|
[PMID: 28214231] |
| Caco-2 | IC50 |
14 μM
Compound: Roscovitine
|
Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs
Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs
|
[PMID: 34601029] |
| Caco-2 | IC50 |
16 μM
Compound: Roscovitin
|
Cytotoxicity against human Caco2 cells assessed as cell growth inhibition
Cytotoxicity against human Caco2 cells assessed as cell growth inhibition
|
[PMID: 26934105] |
| Caco-2 | IC50 |
17 μM
Compound: Roscovitine
|
Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| Caco-2 | IC50 |
3 μM
Compound: Roscovitine
|
Cytotoxicity against human Caco2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay
Cytotoxicity against human Caco2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay
|
[PMID: 26142492] |
| Caco-2 | IC50 |
3 μM
Compound: Roscovitine
|
Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 3342 staining analysis
Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 3342 staining analysis
|
[PMID: 27019296] |
| Caco-2 | IC50 |
5 μM
Compound: Roscovitine
|
Antiproliferative activity against human Caco2 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay
Antiproliferative activity against human Caco2 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay
|
[PMID: 23063566] |
| Caco-2 | IC50 |
6 μM
Compound: Roscovitine
|
Antiproliferative activity against human Caco-2 cells after 72 hrs by imaging analysis
Antiproliferative activity against human Caco-2 cells after 72 hrs by imaging analysis
|
[PMID: 19665384] |
| CAKI-1 | GI50 |
6.3 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human Caki1 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human Caki1 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| CAL-148 | IC50 |
>10 μM
Compound: Roscovitine
|
Antiproliferative activity against human CAL148 cells measured after 72 hrs by CCK8 assay
Antiproliferative activity against human CAL148 cells measured after 72 hrs by CCK8 assay
|
[PMID: 31272794] |
| CCRF-CEM | GI50 |
>100 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by ViaLight assay
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| CCRF-CEM | IC50 |
16.3 μM
Compound: Roscovitine
|
Cytotoxicity against human CEM cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay
Cytotoxicity against human CEM cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay
|
[PMID: 22770608] |
| CCRF-CEM | IC50 |
18.2 μM
Compound: Roscovitine
|
In vitro cytotoxic effect on CEM cancer cell line
In vitro cytotoxic effect on CEM cancer cell line
|
[PMID: 12392733] |
| CH1 | GI50 |
3.25 μM
Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine
|
Growth inhibition of doxorubicin-susceptible human CH1 cells after 96 hrs by sulforhodamine B assay
Growth inhibition of doxorubicin-susceptible human CH1 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 21982796] |
| CH1 | GI50 |
5.4 μM
Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine
|
Growth inhibition of doxorubicin-resistant human CH1 cells after 96 hrs by sulforhodamine B assay
Growth inhibition of doxorubicin-resistant human CH1 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 21982796] |
| ChaGo-K-1 | IC50 |
30.2 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against human ChaGo-K-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against human ChaGo-K-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| COLO 205 | GI50 |
12.6 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human COLO205 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human COLO205 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| COLO 205 | GI50 |
24.9 μM
Compound: Roscovitine
|
Antiproliferative activity against human COLO205 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human COLO205 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21080703] |
| DU-145 | GI50 |
15.8 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human DU145 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human DU145 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| DU-145 | IC50 |
1.9 μM
Compound: 1
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 23623491] |
| DU-145 | IC50 |
18.8 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 mutant human DU-145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 mutant human DU-145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| EKVX | GI50 |
19.9 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human EKVX cells after 72 hrs by ViaLight assay
Antiproliferative activity against human EKVX cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| Epithelial cell | IC50 |
25 μM
Compound: K00020, roscovitine
|
Growth inhibition of human renal epithelial cells after 72 hrs by TUNEL assay
Growth inhibition of human renal epithelial cells after 72 hrs by TUNEL assay
|
[PMID: 18077363] |
| Fibroblast | IC50 |
>20 μM
Compound: Rosco
|
Cytotoxicity against human fibroblasts assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
Cytotoxicity against human fibroblasts assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
|
[PMID: 28214231] |
| Fibroblast | IC50 |
>25 μM
Compound: Roscovitin
|
Cytotoxicity against human fibroblast cells after 48 hrs by Hoechst-33342 staining-based imaging analysis
Cytotoxicity against human fibroblast cells after 48 hrs by Hoechst-33342 staining-based imaging analysis
|
[PMID: 21944287] |
| Fibroblast | IC50 |
>25 μM
Compound: Roscovitine
|
Antiproliferative activity against human fibroblast after 72 hrs by imaging analysis
Antiproliferative activity against human fibroblast after 72 hrs by imaging analysis
|
[PMID: 19665384] |
| Fibroblast | IC50 |
12 μM
Compound: Roscovitine
|
Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| Fibroblast | IC50 |
15 μM
Compound: Roscovitine
|
Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs
Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs
|
[PMID: 34601029] |
| Fibroblast | IC50 |
6 μM
Compound: Roscovitine
|
Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| Fibroblast | IC50 |
7 μM
Compound: Roscovitin
|
Cytotoxicity against human Fibroblasts assessed as cell growth inhibition
Cytotoxicity against human Fibroblasts assessed as cell growth inhibition
|
[PMID: 26934105] |
| G-361 | IC50 |
20.8 μM
Compound: Seliciclib; L2
|
Cytotoxicity against human G361 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method
Cytotoxicity against human G361 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method
|
[PMID: 26741853] |
| G-361 | IC50 |
22.4 μM
Compound: Roscov
|
Cytotoxicity against human G361 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay
Cytotoxicity against human G361 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay
|
[PMID: 26851505] |
| G-361 | IC50 |
22.4 μM
Compound: Roscovitine
|
Cytotoxicity against human G361 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay
Cytotoxicity against human G361 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay
|
[PMID: 22770608] |
| G-361 | IC50 |
22.4 μM
Compound: roscovitine, CYC202, seliciclib
|
Cytotoxicity against human G361 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay
Cytotoxicity against human G361 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay
|
[PMID: 23829517] |
| G-361 | IC50 |
34 μM
Compound: Roscovitine
|
In vitro cytotoxic effect on G361 cancer cell line
In vitro cytotoxic effect on G361 cancer cell line
|
[PMID: 12392733] |
| Granta-519 | IC50 |
25 μM
Compound: K00020, roscovitine
|
Growth inhibition of human Granta519 cells after 72 hrs by TUNEL assay
Growth inhibition of human Granta519 cells after 72 hrs by TUNEL assay
|
[PMID: 18077363] |
| HaCaT | IC50 |
12 μM
Compound: Roscovitine
|
Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| HaCaT | IC50 |
16.7 μM
Compound: Rosco
|
Cytotoxicity against human HaCaT cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
Cytotoxicity against human HaCaT cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
|
[PMID: 28214231] |
| HCC 2998 | GI50 |
31.6 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human HCC2998 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human HCC2998 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| HCT-116 | GI50 |
15.5 μM
Compound: Roscovitine
|
Antiproliferative activity against human HCT116 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human HCT116 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21080703] |
| HCT-116 | GI50 |
5.01 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human HCT116 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human HCT116 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| HCT-116 | GI50 |
5.05 μM
Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine
|
Growth inhibition of human HCT116 cells after 96 hrs by sulforhodamine B assay
Growth inhibition of human HCT116 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 21982796] |
| HCT-116 | IC50 |
10.7 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 wild-type human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 wild-type human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| HCT-116 | IC50 |
14.4 μM
Compound: Roscovitine
|
Cytotoxicity against human HCT116 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay
Cytotoxicity against human HCT116 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay
|
[PMID: 22770608] |
| HCT-116 | IC50 |
14.4 μM
Compound: roscovitine, CYC202, seliciclib
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay
|
[PMID: 23829517] |
| HCT-116 | IC50 |
14.42 μM
Compound: Roscov
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay
|
[PMID: 26851505] |
| HCT-116 | IC50 |
15.54 μM
Compound: Roscovitine
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32773088] |
| HCT-116 | IC50 |
16.38 μM
Compound: (R)-roscovitine
|
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
|
[PMID: 23036956] |
| HCT-116 | IC50 |
17.32 μM
Compound: Roscovitine
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| HCT-116 | IC50 |
2 μM
Compound: Roscovitine
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay
|
[PMID: 26142492] |
| HCT-116 | IC50 |
2 μM
Compound: Roscovitine
|
Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 3342 staining analysis
Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 3342 staining analysis
|
[PMID: 27019296] |
| HCT-116 | IC50 |
5 μM
Compound: Roscovitine
|
Antiproliferative activity against human HCT116 cells after 72 hrs by imaging analysis
Antiproliferative activity against human HCT116 cells after 72 hrs by imaging analysis
|
[PMID: 19665384] |
| HCT-116 | IC50 |
6.76 μM
Compound: Roscovitine
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 32361064] |
| HCT-116 | IC50 |
7 μM
Compound: Roscovitine
|
Antiproliferative activity against human HCT116 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay
Antiproliferative activity against human HCT116 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay
|
[PMID: 23063566] |
| HCT-116 | IC50 |
8 μM
Compound: Rosco
|
Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
|
[PMID: 28214231] |
| HCT-116 | IC50 |
8 μM
Compound: Roscovitin
|
Cytotoxicity against human HCT116 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis
Cytotoxicity against human HCT116 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis
|
[PMID: 21944287] |
| HCT-116 | IC50 |
9 μM
Compound: Roscovitine
|
Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| HCT-116 | IC50 |
9 μM
Compound: Roscovitine
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| HCT-116 | IC50 |
9 μM
Compound: Roscovitine
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs
|
[PMID: 34601029] |
| HCT-116 | IC50 |
9 μM
Compound: Roscovitin
|
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition
|
[PMID: 26934105] |
| HCT-15 | GI50 |
19.9 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human HCT15 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human HCT15 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| HCT-15 | IC50 |
18.3 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 mutant human HCT-15 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 mutant human HCT-15 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| HEK293 | IC50 |
23.4 μM
Compound: Roscovitine
|
Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit
Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit
|
[PMID: 22761000] |
| HEK293 | IC50 |
46.7 μM
Compound: 8a, (R)-roscovitine
|
Antiproliferative activity against HEK293 cells assessed as survival after 48 hrs by MTS reduction assay
Antiproliferative activity against HEK293 cells assessed as survival after 48 hrs by MTS reduction assay
|
[PMID: 18698753] |
| HEK293 | IC50 |
48.9 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human HEK293 cells after 48 hrs by MTS reduction assay
Antiproliferative activity against human HEK293 cells after 48 hrs by MTS reduction assay
|
[PMID: 19128055] |
| HEK293 | IC50 |
5 μM
Compound: roscovitine
|
Inhibition of mouse Dyrk1A autophosphorylation in HEk293 cells
Inhibition of mouse Dyrk1A autophosphorylation in HEk293 cells
|
[PMID: 16698266] |
| HeLa | IC50 |
1.81 μM
Compound: 1
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 23623491] |
| HeLa | IC50 |
11.21 μM
Compound: Roscovitine
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 32361064] |
| HeLa | IC50 |
2.2 μM
Compound: Roscovitine
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 36325400] |
| HeLa | IC50 |
28.6 μM
Compound: roscovitine, CYC202, seliciclib
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay
|
[PMID: 23829517] |
| HeLa S3 | GI50 |
20 μM
Compound: 2
|
Antiproliferative activity against human HeLaS3 cells by sulforhodamine B assay
Antiproliferative activity against human HeLaS3 cells by sulforhodamine B assay
|
[PMID: 19846305] |
| HeLa S3 | GI50 |
20 μM
Compound: 1
|
Growth inhibition of human HeLaS3 cells
Growth inhibition of human HeLaS3 cells
|
[PMID: 19854650] |
| Hep 3B2 | IC50 |
9 μM
Compound: Roscovitine
|
Growth inhibition of human Hep3B cells after 72 hrs by MTS/PMS system based colorimetric assay
Growth inhibition of human Hep3B cells after 72 hrs by MTS/PMS system based colorimetric assay
|
[PMID: 25988923] |
| HepG2 | GI50 |
25.9 μM
Compound: Roscovitine
|
Antiproliferative activity against human HepG2 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human HepG2 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21080703] |
| HepG2 | IC50 |
>100 μM
Compound: Roscovitine
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| HepG2 | IC50 |
11.3 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 wild-type human HepG2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 wild-type human HepG2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| HepG2 | IC50 |
15.47 μM
Compound: (R)-roscovitine
|
Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
|
[PMID: 23036956] |
| HepG2 | IC50 |
15.76 μM
Compound: Roscovitine
|
Antiproliferative activity against human HepG2 cells measured after 72 hrs by CCK8 assay
Antiproliferative activity against human HepG2 cells measured after 72 hrs by CCK8 assay
|
[PMID: 31272794] |
| HepG2 | IC50 |
8.53 μM
Compound: Roscovitine
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 32361064] |
| HL-60(TB) | GI50 |
19.9 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human HL60(TB) cells after 72 hrs by ViaLight assay
Antiproliferative activity against human HL60(TB) cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| HOP-62 | GI50 |
25.1 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human HOP62 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human HOP62 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| HOP-92 | GI50 |
50.1 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human HOP92 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human HOP92 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| HOS | IC50 |
24.3 μM
Compound: Roscovitine
|
Cytotoxicity against human HOS cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay
Cytotoxicity against human HOS cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay
|
[PMID: 22770608] |
| HOS | IC50 |
24.3 μM
Compound: roscovitine, CYC202, seliciclib
|
Cytotoxicity against human HOS cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay
Cytotoxicity against human HOS cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay
|
[PMID: 23829517] |
| HOS | IC50 |
32 μM
Compound: Roscovitine
|
In vitro cytotoxic effect on HOS cancer cell line
In vitro cytotoxic effect on HOS cancer cell line
|
[PMID: 12392733] |
| HS27 | IC50 |
22.2 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against human HS27 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against human HS27 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| Hs-578T | GI50 |
12.8 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human Hs 578T cells after 72 hrs by ViaLight assay
Antiproliferative activity against human Hs 578T cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| HT-1080 | IC50 |
16.8 μM
Compound: Roscovitine
|
Antiproliferative activity against human HT1080 cells after 3 days by SRB assay
Antiproliferative activity against human HT1080 cells after 3 days by SRB assay
|
[PMID: 20361800] |
| HT-1080 | IC50 |
9.62 μM
Compound: (R)-roscovitine
|
Cytotoxicity against human HT1080 cells after 48 hrs by SRB assay
Cytotoxicity against human HT1080 cells after 48 hrs by SRB assay
|
[PMID: 23036956] |
| HT-1376 | IC50 |
18.4 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 mutant human HT-1376 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 mutant human HT-1376 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| HT-29 | GI50 |
19.9 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human HT29 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human HT29 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| HT-29 | GI50 |
6.4 μM
Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine
|
Growth inhibition of human HT-29 cells after 96 hrs by sulforhodamine B assay
Growth inhibition of human HT-29 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 21982796] |
| HT-29 | IC50 |
>100 μM
Compound: Roscovitine
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| HT-29 | IC50 |
11.63 μM
Compound: (R)-roscovitine
|
Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay
|
[PMID: 23036956] |
| HT-29 | IC50 |
14.6 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 mutant human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 mutant human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| Huh-7 | IC50 |
10 μM
Compound: Roscovitin
|
Cytotoxicity against human HuH7 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis
Cytotoxicity against human HuH7 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis
|
[PMID: 21944287] |
| Huh-7 | IC50 |
12 μM
Compound: Roscovitine
|
Antiproliferative activity against human HuH7 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay
Antiproliferative activity against human HuH7 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay
|
[PMID: 23063566] |
| Huh-7 | IC50 |
14 μM
Compound: Roscovitine
|
Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| Huh-7 | IC50 |
15.4 μM
Compound: Rosco
|
Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
|
[PMID: 28214231] |
| Huh-7 | IC50 |
20 μM
Compound: Roscovitine
|
Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| Huh-7 | IC50 |
5 μM
Compound: Roscovitine
|
Antiproliferative activity against human HuH7 cells after 72 hrs by imaging analysis
Antiproliferative activity against human HuH7 cells after 72 hrs by imaging analysis
|
[PMID: 19665384] |
| Huh-7 | IC50 |
5 μM
Compound: Roscovitine
|
Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay
Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay
|
[PMID: 26142492] |
| Huh-7 | IC50 |
5 μM
Compound: Roscovitine
|
Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 3342 staining analysis
Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 3342 staining analysis
|
[PMID: 27019296] |
| Huh-7 | IC50 |
9 μM
Compound: Roscovitine
|
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs
|
[PMID: 34601029] |
| HUVEC | GI50 |
3.7 μM
Compound: Roscovitine
|
Antiproliferative activity against human HUVEC cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human HUVEC cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21080703] |
| IGROV-1 | GI50 |
6.3 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human IGROV1 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human IGROV1 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| IMR-32 | IC50 |
17 μM
Compound: (R)-Roscovitine; Roscovitine
|
Antiproliferative activity against human IMR32 cells after 2 days by XTT assay
Antiproliferative activity against human IMR32 cells after 2 days by XTT assay
|
[PMID: 30199702] |
| IMR-90 | IC50 |
>100 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against human IMR-90 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against human IMR-90 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| K562 | GI50 |
50.1 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human K562 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human K562 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| K562 | IC50 |
>100 μM
Compound: Roscovitine
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| K562 | IC50 |
>20 μM
Compound: Roscovitine
|
Antiproliferative activity against human K562 cells after 3 days by SRB assay
Antiproliferative activity against human K562 cells after 3 days by SRB assay
|
[PMID: 20361800] |
| K562 | IC50 |
30.9 μM
Compound: Seliciclib; L2
|
Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method
Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method
|
[PMID: 26741853] |
| K562 | IC50 |
40 μM
Compound: Roscovitine
|
In vitro cytotoxic effect on K562 cancer cell line
In vitro cytotoxic effect on K562 cancer cell line
|
[PMID: 12392733] |
| K562 | IC50 |
40 μM
Compound: Roscovitine
|
Cytotoxic property against K562 cell line was determined
Cytotoxic property against K562 cell line was determined
|
[PMID: 12941319] |
| K562 | IC50 |
42 μM
Compound: roscovitine
|
Cytotoxicity against human K562 cells after 72 hrs using Calcein AM by fluorescence assay
Cytotoxicity against human K562 cells after 72 hrs using Calcein AM by fluorescence assay
|
[PMID: 25757603] |
| K562 | IC50 |
42 μM
Compound: Roskovotin
|
Antiproliferative activity against human K562 cells
Antiproliferative activity against human K562 cells
|
[PMID: 23352483] |
| K562 | IC50 |
45.5 μM
Compound: Roscov
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay
|
[PMID: 26851505] |
| K562 | IC50 |
45.5 μM
Compound: Roscovitine
|
Cytotoxicity against human K562 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay
Cytotoxicity against human K562 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay
|
[PMID: 22770608] |
| K562 | IC50 |
45.5 μM
Compound: Roscovitine
|
Cytotoxicity against human K562 cells after 72 hrs by calcein-AM assay
Cytotoxicity against human K562 cells after 72 hrs by calcein-AM assay
|
[PMID: 23981532] |
| K562 | IC50 |
45.5 μM
Compound: roscovitine, CYC202, seliciclib
|
Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay
Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay
|
[PMID: 23829517] |
| K562 | IC50 |
45.5 μM
Compound: Roscovitine
|
Cytotoxicity against human K562 cells
Cytotoxicity against human K562 cells
|
[PMID: 27189674] |
| KB | IC50 |
24.6 μM
Compound: Roscovitine
|
Growth inhibition of human KB cells after 72 hrs by MTS/PMS system based colorimetric assay
Growth inhibition of human KB cells after 72 hrs by MTS/PMS system based colorimetric assay
|
[PMID: 25988923] |
| KB | IC50 |
30.1 μM
Compound: Roscovitine
|
Antiproliferative activity against human KB cells after 3 days by SRB assay
Antiproliferative activity against human KB cells after 3 days by SRB assay
|
[PMID: 20361800] |
| KM12 | GI50 |
15 μM
Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine
|
Growth inhibition of human KM12 cells after 96 hrs by sulforhodamine B assay
Growth inhibition of human KM12 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 21982796] |
| KM12 | GI50 |
5.01 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human KM12 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human KM12 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| L02 | IC50 |
20.48 μM
Compound: (R)-roscovitine
|
Cytotoxicity against human L02 cells after 48 hrs by SRB assay
Cytotoxicity against human L02 cells after 48 hrs by SRB assay
|
[PMID: 23036956] |
| LoVo | IC50 |
9.3 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 wild-type human LoVo cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 wild-type human LoVo cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| LOX IMVI | GI50 |
12.6 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human LOXIMVI cells after 72 hrs by ViaLight assay
Antiproliferative activity against human LOXIMVI cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| LP-1 | IC50 |
12.68 μM
Compound: CYC202, R-roscovitine
|
Cytotoxicity against human LP-1 cells after 72 hrs by alamar blue assay
Cytotoxicity against human LP-1 cells after 72 hrs by alamar blue assay
|
[PMID: 15958589] |
| M14 | GI50 |
25.1 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human M14 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human M14 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| Malme-3M | GI50 |
19.9 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human MALME-3M cells after 72 hrs by ViaLight assay
Antiproliferative activity against human MALME-3M cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| MCF-10A | GI50 |
16.3 μM
Compound: Roscovitine
|
Antiproliferative activity against human MCF10A cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF10A cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21080703] |
| MCF7 | GI50 |
12.6 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human MCF7 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human MCF7 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| MCF7 | GI50 |
7.8 μM
Compound: Roscovitine
|
Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21080703] |
| MCF7 | IC50 |
>100 μM
Compound: Roscovitine
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| MCF7 | IC50 |
10.2 μM
Compound: Rosco
|
Cytotoxicity against human MCF7 assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
Cytotoxicity against human MCF7 assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
|
[PMID: 28214231] |
| MCF7 | IC50 |
10.9 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 wild-type human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 wild-type human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| MCF7 | IC50 |
11 μM
Compound: roscovitine
|
Cytotoxicity against human MCF7 cells after 72 hrs using Calcein AM by fluorescence assay
Cytotoxicity against human MCF7 cells after 72 hrs using Calcein AM by fluorescence assay
|
[PMID: 25757603] |
| MCF7 | IC50 |
11 μM
Compound: Roscovitine
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation
|
[PMID: 26698538] |
| MCF7 | IC50 |
11 μM
Compound: Roskovotin
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 23352483] |
| MCF7 | IC50 |
11.1 μM
Compound: Roscovitine
|
In vitro cytotoxic effect on MCF-7 cancer cell line
In vitro cytotoxic effect on MCF-7 cancer cell line
|
[PMID: 12392733] |
| MCF7 | IC50 |
11.1 μM
Compound: Roscovitine
|
Cytotoxic property against MCF-7 cell line was determined
Cytotoxic property against MCF-7 cell line was determined
|
[PMID: 12941319] |
| MCF7 | IC50 |
12.22 μM
Compound: (R)-roscovitine
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 23036956] |
| MCF7 | IC50 |
12.25 μM
Compound: Roscov
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay
|
[PMID: 26851505] |
| MCF7 | IC50 |
12.3 μM
Compound: Roscovitine
|
Cytotoxicity against human MCF7 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay
Cytotoxicity against human MCF7 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay
|
[PMID: 22770608] |
| MCF7 | IC50 |
12.3 μM
Compound: Roscovitine
|
Cytotoxicity against human MCF7 cells after 72 hrs by calcein-AM assay
Cytotoxicity against human MCF7 cells after 72 hrs by calcein-AM assay
|
[PMID: 23981532] |
| MCF7 | IC50 |
12.3 μM
Compound: roscovitine, CYC202, seliciclib
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay
|
[PMID: 23829517] |
| MCF7 | IC50 |
12.3 μM
Compound: Roscovitine
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 27189674] |
| MCF7 | IC50 |
14.7 μM
Compound: Roscovitine
|
Antiproliferative activity against human MCF7 cells after 3 days by SRB assay
Antiproliferative activity against human MCF7 cells after 3 days by SRB assay
|
[PMID: 20361800] |
| MCF7 | IC50 |
19.6 μM
Compound: Roscovitine
|
Growth inhibition of human MCF7 cells after 72 hrs by MTS/PMS system based colorimetric assay
Growth inhibition of human MCF7 cells after 72 hrs by MTS/PMS system based colorimetric assay
|
[PMID: 25988923] |
| MCF7 | IC50 |
20.2 μM
Compound: Roscovitine
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by calcien AM dye based fluorescence analysis
Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by calcien AM dye based fluorescence analysis
|
[PMID: 23399722] |
| MCF7 | IC50 |
27.2 μM
Compound: Seliciclib; L2
|
Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method
Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method
|
[PMID: 26741853] |
| MCF7 | IC50 |
3.98 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23623491] |
| MCF7 | IC50 |
55.01 μM
Compound: R-Roscovitine
|
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by WST-1 assay
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by WST-1 assay
|
[PMID: 21440449] |
| MCF7 | IC50 |
9 μM
Compound: Roscovitine
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| MCF7 | IC50 |
9 μM
Compound: Roscovitine
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs
|
[PMID: 34601029] |
| MDA-MB-231 | GI50 |
22.6 μM
Compound: Roscovitine
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21080703] |
| MDA-MB-231 | GI50 |
39.8 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| MDA-MB-231 | IC50 |
12 μM
Compound: Roscovitine
|
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay
|
[PMID: 23063566] |
| MDA-MB-231 | IC50 |
12 μM
Compound: Roscovitine
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| MDA-MB-231 | IC50 |
15 μM
Compound: Roscovitin
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis
|
[PMID: 21944287] |
| MDA-MB-231 | IC50 |
15 μM
Compound: Roscovitine
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| MDA-MB-231 | IC50 |
15 μM
Compound: 2
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability
|
[PMID: 31514062] |
| MDA-MB-231 | IC50 |
15 μM
Compound: Roscovitin
|
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition
|
[PMID: 26934105] |
| MDA-MB-231 | IC50 |
16.8 μM
Compound: Rosco
|
Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
|
[PMID: 28214231] |
| MDA-MB-231 | IC50 |
17 μM
Compound: Roscovitine
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs
|
[PMID: 34601029] |
| MDA-MB-231 | IC50 |
3 μM
Compound: Roscovitine
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay
|
[PMID: 26142492] |
| MDA-MB-231 | IC50 |
3 μM
Compound: Roscovitine
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 3342 staining analysis
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 3342 staining analysis
|
[PMID: 27019296] |
| MDA-MB-231 | IC50 |
54.64 μM
Compound: R-Roscovitine
|
Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells after 48 hrs by WST-1 assay
Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells after 48 hrs by WST-1 assay
|
[PMID: 21440449] |
| MDA-MB-435 | GI50 |
12.6 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| MDA-MB-435S | IC50 |
17.5 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 mutant human MDA-MB-435S cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 mutant human MDA-MB-435S cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| MDA-MB-468 | IC50 |
18 μM
Compound: Roscovitine
|
Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs
Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs
|
[PMID: 34601029] |
| MES-SA | IC50 |
11.9 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| MES-SA/Dx5 | IC50 |
7.9 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| MGC-803 | IC50 |
>100 μM
Compound: Roscovitine
|
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| MIA PaCa-2 | IC50 |
12 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 wild-type human MIA PaCa-2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 wild-type human MIA PaCa-2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| MIA PaCa-2 | IC50 |
13.9 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 mutant human MIA PaCa-2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 mutant human MIA PaCa-2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| MIA PaCa-2 | IC50 |
15.2 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| MIA PaCa-2 | IC50 |
18214 nM
Compound: Roscovitine
|
Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by prestoblue assay
Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by prestoblue assay
|
[PMID: 30343954] |
| MKN-45 | IC50 |
7.6 μM
Compound: Roscovitine
|
Growth inhibition of human MKN45 cells after 72 hrs by MTS/PMS system based colorimetric assay
Growth inhibition of human MKN45 cells after 72 hrs by MTS/PMS system based colorimetric assay
|
[PMID: 25988923] |
| MOLT-4 | GI50 |
25.1 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human MOLT4 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human MOLT4 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| NCI/ADR-RES | GI50 |
6.3 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human NCI/ADR-RES cells after 72 hrs by ViaLight assay
Antiproliferative activity against human NCI/ADR-RES cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| NCI-H1299 | IC50 |
83.02 μM
Compound: Roscovitine
|
Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| NCI-H226 | GI50 |
19.9 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human NCI-H226 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human NCI-H226 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| NCI-H23 | GI50 |
12.6 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human NCI-H23 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human NCI-H23 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| NCI-H322M | GI50 |
31.6 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human NCI-H322M cells after 72 hrs by ViaLight assay
Antiproliferative activity against human NCI-H322M cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| NCI-H460 | GI50 |
25.1 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human NCI-H460 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human NCI-H460 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| NCI-H460 | IC50 |
11.6 μM
Compound: Roscovitine
|
Growth inhibition of human NCI-H460 cells after 72 hrs by MTS/PMS system based colorimetric assay
Growth inhibition of human NCI-H460 cells after 72 hrs by MTS/PMS system based colorimetric assay
|
[PMID: 25988923] |
| NCI-H460 | IC50 |
11.9 μM
Compound: Roscovitine
|
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 32361064] |
| NCI-H460 | IC50 |
13.1 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 wild-type human NCI-H460 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 wild-type human NCI-H460 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| NCI-H522 | GI50 |
15.8 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human NCI-H522 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human NCI-H522 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| NCI-H69 | IC50 |
26 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against p53 mutant human NCI-H69 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against p53 mutant human NCI-H69 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| NCI-H727 | IC50 |
>20 μM
Compound: Rosco
|
Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
|
[PMID: 28214231] |
| NCI-H727 | IC50 |
20 μM
Compound: Roscovitine
|
Antiproliferative activity against human NCI-H727 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay
Antiproliferative activity against human NCI-H727 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay
|
[PMID: 23063566] |
| NCI-H727 | IC50 |
20 μM
Compound: Roscovitine
|
Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| NCI-H727 | IC50 |
28 μM
Compound: Roscovitine
|
Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| NCI-H727 | IC50 |
4 μM
Compound: Roscovitine
|
Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay
Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay
|
[PMID: 26142492] |
| NCI-H727 | IC50 |
4 μM
Compound: Roscovitine
|
Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 3342 staining analysis
Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 3342 staining analysis
|
[PMID: 27019296] |
| NCI-H929 | IC50 |
8.84 μM
Compound: CYC202, R-roscovitine
|
Cytotoxicity against human NCI-H929 cells after 72 hrs by alamar blue assay
Cytotoxicity against human NCI-H929 cells after 72 hrs by alamar blue assay
|
[PMID: 15958589] |
| Non-small cell lung cancer cell line | GI50 |
23.6 μM
Compound: Roscovitine
|
Anticancer activity against human Non-small cell lung cancer cell line assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Non-small cell lung cancer cell line assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Non-small cell lung cancer cells | GI50 |
23.6 μM
Compound: Roscovitine
|
Anticancer activity against human Non-small cell lung cancer cell line assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Non-small cell lung cancer cell line assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Oocyte | IC50 |
0.2 μM
Compound: 26
|
Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.
Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis.
|
[PMID: 9046330] |
| Oocyte | IC50 |
0.33 μM
Compound: (R)-roscovitine
|
Inhibition of starfish oocytes CDK1/cyclin B
Inhibition of starfish oocytes CDK1/cyclin B
|
[PMID: 19128055] |
| Oocyte | IC50 |
0.65 nM
Compound: 3; CYC202
|
Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis
Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis
|
[PMID: 35485642] |
| Oocyte | IC50 |
650 nM
Compound: 2
|
Inhibition of starfish oocyte CDK1 using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by radiometric scintillation assay
Inhibition of starfish oocyte CDK1 using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by radiometric scintillation assay
|
[PMID: 35235745] |
| Oocyte | IC50 |
650 nM
Compound: roscovitine
|
In vitro inhibitory activity against Cyclin-dependent kinase 1-cyclin B complex from starfish oocytes
In vitro inhibitory activity against Cyclin-dependent kinase 1-cyclin B complex from starfish oocytes
|
[PMID: 10753466] |
| OPM-2 | IC50 |
18.46 μM
Compound: CYC202, R-roscovitine
|
Cytotoxicity against human OPM2 cells after 72 hrs by alamar blue assay
Cytotoxicity against human OPM2 cells after 72 hrs by alamar blue assay
|
[PMID: 15958589] |
| OVCAR-3 | GI50 |
12.6 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human OVCAR-3 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human OVCAR-3 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| OVCAR-3 | IC50 |
37 μM
Compound: (R)-Roscovitine; Roscovitine
|
Antiproliferative activity against human OVCAR3 cells after 2 days by XTT assay
Antiproliferative activity against human OVCAR3 cells after 2 days by XTT assay
|
[PMID: 30199702] |
| OVCAR-4 | GI50 |
31.6 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human OVCAR4 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human OVCAR4 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| OVCAR-5 | GI50 |
39.8 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human OVCAR5 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human OVCAR5 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| Panel breast (Carcinoma cell lines) | GI50 |
22.7 μM
Compound: Roscovitine
|
Anticancer activity against human Panel breast (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel breast (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel breast cells | GI50 |
22.7 μM
Compound: Roscovitine
|
Anticancer activity against human Panel breast (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel breast (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel CNS (Carcinoma cell lines) | GI50 |
24.7 μM
Compound: Roscovitine
|
Anticancer activity against human Panel CNS (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel CNS (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel colon (Carcinoma cell lines) | GI50 |
24.8 μM
Compound: Roscovitine
|
Anticancer activity against human Panel colon (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel colon (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel colon cells | GI50 |
24.8 μM
Compound: Roscovitine
|
Anticancer activity against human Panel colon (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel colon (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel leukemia (Carcinoma cell lines) | GI50 |
37.5 μM
Compound: Roscovitine
|
Anticancer activity against human Panel leukemia (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel leukemia (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel leukemia cells | GI50 |
37.5 μM
Compound: Roscovitine
|
Anticancer activity against human Panel leukemia (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel leukemia (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel melanoma (Carcinoma cell lines) | GI50 |
14.8 μM
Compound: Roscovitine
|
Anticancer activity against human Panel melanoma (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel melanoma (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel melanoma cells | GI50 |
14.8 μM
Compound: Roscovitine
|
Anticancer activity against human Panel melanoma (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel melanoma (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel ovarian (Carcinoma cell lines) | GI50 |
29.3 μM
Compound: Roscovitine
|
Anticancer activity against human Panel ovarian (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel ovarian (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel ovarian cells | GI50 |
29.3 μM
Compound: Roscovitine
|
Anticancer activity against human Panel ovarian (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel ovarian (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel prostate (Carcinoma cell lines) | GI50 |
17.9 μM
Compound: Roscovitine
|
Anticancer activity against human Panel prostate (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel prostate (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel prostate cells | GI50 |
17.9 μM
Compound: Roscovitine
|
Anticancer activity against human Panel prostate (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel prostate (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel renal (Carcinoma cell lines) | GI50 |
24.9 μM
Compound: Roscovitine
|
Anticancer activity against human Panel renal (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel renal (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| Panel renal cells | GI50 |
24.9 μM
Compound: Roscovitine
|
Anticancer activity against human Panel renal (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
Anticancer activity against human Panel renal (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay
|
[PMID: 27744184] |
| PBMC | CC50 |
22 μM
Compound: 48; CYC202, aSbR-21
|
Cytotoxicity against human PBMC
Cytotoxicity against human PBMC
|
[PMID: 33539089] |
| PC-3 | GI50 |
19.9 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human PC3 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human PC3 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| PC-3 | GI50 |
25.2 μM
Compound: Roscovitine
|
Antiproliferative activity against human PC3 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human PC3 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21080703] |
| PC-3 | IC50 |
>100 μM
Compound: Roscovitine
|
Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| PC-3 | IC50 |
10 μM
Compound: Roscovitine
|
Antiproliferative activity against human PC3 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay
Antiproliferative activity against human PC3 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay
|
[PMID: 23063566] |
| PC-3 | IC50 |
10 μM
Compound: Roscovitine
|
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| PC-3 | IC50 |
11 μM
Compound: Roscovitine
|
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 48 hrs
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 48 hrs
|
[PMID: 34601029] |
| PC-3 | IC50 |
12 μM
Compound: Roscovitine
|
Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| PC-3 | IC50 |
12 μM
Compound: Roscovitin
|
Cytotoxicity against human PC3 cells assessed as cell growth inhibition
Cytotoxicity against human PC3 cells assessed as cell growth inhibition
|
[PMID: 26934105] |
| PC-3 | IC50 |
16.5 μM
Compound: Rosco
|
Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
|
[PMID: 28214231] |
| PC-3 | IC50 |
2 μM
Compound: Roscovitine
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay
|
[PMID: 26142492] |
| PC-3 | IC50 |
2 μM
Compound: Roscovitine
|
Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 3342 staining analysis
Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 3342 staining analysis
|
[PMID: 27019296] |
| PC-3 | IC50 |
8 μM
Compound: Roscovitin
|
Cytotoxicity against human PC3 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis
Cytotoxicity against human PC3 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis
|
[PMID: 21944287] |
| PC-3 | IC50 |
8 μM
Compound: Roscovitine
|
Antiproliferative activity against human PC3 cells after 72 hrs by imaging analysis
Antiproliferative activity against human PC3 cells after 72 hrs by imaging analysis
|
[PMID: 19665384] |
| RL | IC50 |
0.9 μM
Compound: Rosco
|
Cytotoxicity against human RL assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
Cytotoxicity against human RL assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay
|
[PMID: 28214231] |
| RPMI-8226 | IC50 |
19.5 μM
Compound: CYC202, R-roscovitine
|
Cytotoxicity against human RPM18226 cells after 72 hrs by alamar blue assay
Cytotoxicity against human RPM18226 cells after 72 hrs by alamar blue assay
|
[PMID: 15958589] |
| RXF 393 | GI50 |
5 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human RFX393 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human RFX393 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| SAOS-2 | GI50 |
13.9 μM
Compound: Roscovitine
|
Antiproliferative activity against human Saos2 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human Saos2 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21080703] |
| Sf21 | IC50 |
0.5 μM
Compound: Roscovitine
|
Inhibition of CDK2/cyclin A expressed in baculovirus infected insect Sf21 cells using [gamma-P32]ATP and histone H1 as substrate after 10 mins by radiometric assay
Inhibition of CDK2/cyclin A expressed in baculovirus infected insect Sf21 cells using [gamma-P32]ATP and histone H1 as substrate after 10 mins by radiometric assay
|
[PMID: 22000924] |
| Sf21 | IC50 |
0.5 μM
Compound: Roscovitine
|
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP
|
[PMID: 23933045] |
| Sf21 | IC50 |
100 nM
Compound: Roscovitine
|
Inhibition of CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf21 insect cells in presence of [gamma33P]ATP
Inhibition of CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf21 insect cells in presence of [gamma33P]ATP
|
[PMID: 32150405] |
| Sf21 | IC50 |
15 μM
Compound: Roscovitine
|
Inhibition of CDK4/cyclin D expressed in baculovirus infected insect Sf21 cells using [gamma-P32]ATP and histone H1 as substrate after 10 mins by radiometric assay
Inhibition of CDK4/cyclin D expressed in baculovirus infected insect Sf21 cells using [gamma-P32]ATP and histone H1 as substrate after 10 mins by radiometric assay
|
[PMID: 22000924] |
| Sf21 | IC50 |
193 nM
Compound: Roscovitine
|
Inhibition of wild-type human N-terminal GST-tagged CDK2/cycA2 expressed in Sf21 insect cells using FAM-labelled substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay
Inhibition of wild-type human N-terminal GST-tagged CDK2/cycA2 expressed in Sf21 insect cells using FAM-labelled substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay
|
[PMID: 31272794] |
| SF-268 | GI50 |
19.9 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human SF268 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human SF268 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| SF-268 | IC50 |
8.8 μM
Compound: Roscovitine
|
Growth inhibition of human SF268 cells after 72 hrs by MTS/PMS system based colorimetric assay
Growth inhibition of human SF268 cells after 72 hrs by MTS/PMS system based colorimetric assay
|
[PMID: 25988923] |
| SF-295 | GI50 |
25.1 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human SF295 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human SF295 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| SF-539 | GI50 |
15.8 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human SF539 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human SF539 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| Sf9 | IC50 |
>100 μM
Compound: Roscovitine
|
Inhibition of recombinant Abl kinase (unknown origin) expressed in Sf9 cells using GGEAIYAAPFKK as substrate in presence of [gamma33P]ATP
Inhibition of recombinant Abl kinase (unknown origin) expressed in Sf9 cells using GGEAIYAAPFKK as substrate in presence of [gamma33P]ATP
|
[PMID: 24681986] |
| Sf9 | IC50 |
0.1 μM
Compound: 24, CYC202, Seliciclib
|
Inhibition of His-6-tagged recombinant human CDK2/cyclinE expressed in baculovirus-infected sf9 cells using histone H1 as substrate after 10 mins by liquid scintillation counting in presence of [gamma-32P]ATP
Inhibition of His-6-tagged recombinant human CDK2/cyclinE expressed in baculovirus-infected sf9 cells using histone H1 as substrate after 10 mins by liquid scintillation counting in presence of [gamma-32P]ATP
|
[PMID: 24417566] |
| Sf9 | IC50 |
0.1 μM
Compound: Roscovitine
|
Inhibition of CDK2/cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate in presence of [gamma33P]ATP
Inhibition of CDK2/cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate in presence of [gamma33P]ATP
|
[PMID: 24681986] |
| Sf9 | IC50 |
0.158 μM
Compound: Roscov
|
Inhibition of CDK2/Cyclin E (unknown origin) expressed in sf9 cells using histone H1 as substrate in presence of [gamma33P]-ATP
Inhibition of CDK2/Cyclin E (unknown origin) expressed in sf9 cells using histone H1 as substrate in presence of [gamma33P]-ATP
|
[PMID: 26851505] |
| Sf9 | IC50 |
0.2 μM
Compound: Seliciclib; L2
|
Inhibition of CDK2/Cyclin E (unknown origin) expressed in baculoviral infected insect Sf9 cells using histone H1 as substrate in presence of [gamma-33P]ATP
Inhibition of CDK2/Cyclin E (unknown origin) expressed in baculoviral infected insect Sf9 cells using histone H1 as substrate in presence of [gamma-33P]ATP
|
[PMID: 26741853] |
| Sf9 | IC50 |
0.27 μM
Compound: Roscovitine
|
Inhibition of recombinant full length N-terminal GST tagged human CDK5/p25 expressed in baculovirus infected sf9 cells using histone H1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay
Inhibition of recombinant full length N-terminal GST tagged human CDK5/p25 expressed in baculovirus infected sf9 cells using histone H1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay
|
[PMID: 31098000] |
| Sf9 | IC50 |
0.49 μM
Compound: 24, CYC202, Seliciclib
|
Inhibition of His-6-tagged recombinant human CDK7/cyclinH expressed in baculovirus-infected sf9 cells using biotinyl-Ahx-(YSPTSPS)4 as substrate after 45 mins by liquid scintillation counting in presence of [gamma-32P]ATP
Inhibition of His-6-tagged recombinant human CDK7/cyclinH expressed in baculovirus-infected sf9 cells using biotinyl-Ahx-(YSPTSPS)4 as substrate after 45 mins by liquid scintillation counting in presence of [gamma-32P]ATP
|
[PMID: 24417566] |
| Sf9 | IC50 |
0.7 μM
Compound: Roscovitine
|
Inhibition of GST-fused CDK2/cyclin A (unknown origin) expressed in baculovirus infected Sf9 cells after 10 min in presence of [gamma-32PP]ATP
Inhibition of GST-fused CDK2/cyclin A (unknown origin) expressed in baculovirus infected Sf9 cells after 10 min in presence of [gamma-32PP]ATP
|
10.1007/s00044-009-9233-5 |
| Sf9 | IC50 |
0.7 μM
Compound: Roscovitine
|
Inhibition of GST-fused CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf9 cells after 10 min in presence of [gamma-32PP]ATP
Inhibition of GST-fused CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf9 cells after 10 min in presence of [gamma-32PP]ATP
|
10.1007/s00044-009-9233-5 |
| Sf9 | IC50 |
170 nM
Compound: roscovitine, CYC202, seliciclib
|
Inhibition of human recombinant CDK2/Cyclin E expressed in baculovirus infected sf9 cells using histone H1 as substrate
Inhibition of human recombinant CDK2/Cyclin E expressed in baculovirus infected sf9 cells using histone H1 as substrate
|
[PMID: 23829517] |
| Sf9 | IC50 |
180 nM
Compound: Roscovitine
|
Inhibition of CDK2/Cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate
Inhibition of CDK2/Cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate
|
[PMID: 22770608] |
| Sf9 | IC50 |
2.69 μM
Compound: 24, CYC202, Seliciclib
|
Inhibition of His-6-tagged recombinant human CDK1/cyclinB1 expressed in baculovirus-infected sf9 cells by liquid scintillation counting in presence of [gamma-32P]ATP
Inhibition of His-6-tagged recombinant human CDK1/cyclinB1 expressed in baculovirus-infected sf9 cells by liquid scintillation counting in presence of [gamma-32P]ATP
|
[PMID: 24417566] |
| SH-SY5Y | IC50 |
16.1 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTS reduction assay
Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTS reduction assay
|
[PMID: 19128055] |
| SH-SY5Y | IC50 |
17 μM
Compound: Ros, Seliciclib
|
Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTS reduction assay
Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTS reduction assay
|
[PMID: 22982525] |
| SH-SY5Y | IC50 |
17.4 μM
Compound: (R)-roscovitine
|
Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTS assay
Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTS assay
|
[PMID: 23218601] |
| SH-SY5Y | IC50 |
17.5 μM
Compound: 8a, (R)-roscovitine
|
Antiproliferative activity against human SH-SY5Y cells assessed as survival after 48 hrs by MTS reduction assay
Antiproliferative activity against human SH-SY5Y cells assessed as survival after 48 hrs by MTS reduction assay
|
[PMID: 18698753] |
| SH-SY5Y | IC50 |
21 μM
Compound: (R)-Roscovitine; Roscovitine
|
Antiproliferative activity against human SH-SY5Y cells after 2 days by XTT assay
Antiproliferative activity against human SH-SY5Y cells after 2 days by XTT assay
|
[PMID: 30199702] |
| SH-SY5Y | IC50 |
41 nM
Compound: 2
|
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability by MTS assay
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability by MTS assay
|
[PMID: 30639897] |
| SiHa | IC50 |
2.69 μM
Compound: Roscovitine
|
Cytotoxicity against human SiHa cells by MTT assay
Cytotoxicity against human SiHa cells by MTT assay
|
[PMID: 36325400] |
| SK-MEL-2 | GI50 |
15.8 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| SK-MEL-5 | GI50 |
10 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human SK-MEL-5 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human SK-MEL-5 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| SK-OV-3 | GI50 |
35.7 μM
Compound: Roscovitine
|
Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21080703] |
| SK-OV-3 | GI50 |
79.4 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human SKOV3 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human SKOV3 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| SNB-75 | GI50 |
12.6 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human SNB75 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human SNB75 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| SNU-638 | IC50 |
9.77 μM
Compound: Roscovitine
|
Antiproliferative activity against human SNU638 cells after 3 days by SRB assay
Antiproliferative activity against human SNU638 cells after 3 days by SRB assay
|
[PMID: 20361800] |
| SR | GI50 |
5.01 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human SR cells after 72 hrs by ViaLight assay
Antiproliferative activity against human SR cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| SW-620 | GI50 |
79.4 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human SW620 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human SW620 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| T47D | GI50 |
16.8 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human T47D cells after 72 hrs by ViaLight assay
Antiproliferative activity against human T47D cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| T-cell | IC50 |
600 nM
Compound: Seliciclib
|
Inhibition of CDK9/Cyclin T (unknown origin)
Inhibition of CDK9/Cyclin T (unknown origin)
|
[PMID: 19169685] |
| TK-10 | GI50 |
63.1 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human TK10 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human TK10 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| U-251 | GI50 |
50.1 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human U251 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human U251 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| U-266 | IC50 |
17.93 μM
Compound: CYC202, R-roscovitine
|
Cytotoxicity against human U266 cells after 72 hrs by alamar blue assay
Cytotoxicity against human U266 cells after 72 hrs by alamar blue assay
|
[PMID: 15958589] |
| UACC-62 | GI50 |
7.9 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human UACC62 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human UACC62 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| UO-31 | GI50 |
12.6 μM
Compound: (R)-roscovitine
|
Antiproliferative activity against human UO31 cells after 72 hrs by ViaLight assay
Antiproliferative activity against human UO31 cells after 72 hrs by ViaLight assay
|
[PMID: 19128055] |
| WI-38 | IC50 |
24 μM
Compound: Chemicel probe : R-CYC202
|
Cytotoxicity against human WI-38 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Cytotoxicity against human WI-38 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 12432547] |
| WI-38 | IC50 |
24.12 μM
Compound: Roscovitine
|
Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32773088] |
(R)-Roscovitine (Seliciclib) displays high efficiency and high selectivity towards some cyclin-dependent kinases. The kinase specificity of Seliciclib is investigated with 25 highly purified kinases (including protein kinase A, G and C isoforms, myosin light-chain kinase, casein kinase 2, IR tyrosine kinase, c-src, v-abl). Most kinases are not significantly inhibited by (R)-Roscovitine. Cdc2, Cdk2, and Cdk5 only are substantially inhibited (IC50 values of 0.65, 0.7, and 0.2 μM, respectively). Cdk4k and Cdk6 are very poorly inhibited by (R)-Roscovitine (IC50>100 μM). Extracellular regulated kinases erk1 and erk2 are inhibited with an IC50 of 34 μM and 14 μM, respectively. (R)-Roscovitine inhibits the proliferation of mammalian cell lines with an average IC50 of 16 μM[1]. (R)-Roscovitine (Seliciclib) decreases the level of CDK5 and p35 with upregulation of E-cadherin, but downregulation of Vimentin and Collagen IV. Moreover, (R)-Roscovitine inhibits the ability of high glucose cultured NRK52E cells to migrate and invade[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 186692-46-6
-
Appearance Solid
-
Molecular Weight 354.45
-
Formula C19H26N6O
-
Color White to off-white
-
SMILES
OC[C@H](NC1=NC(NCC2=CC=CC=C2)=C3C(N(C=N3)C(C)C)=N1)CC
-
Synonyms
Seliciclib; CYC202
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (35)
-
Journal Impact Factor
-
Most Recent
-
Nature
2020 Sep;585(7824):293-297. PMID: 32494016 -
Nat Cell Biol
Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition. [Abstract]2024 Oct;26(10):1773-1789. PMID: 39304713 -
Nat Commun
Functional optic tract rewiring via subtype- and target-specific axonal regeneration and presynaptic activity enhancement. [Abstract]2025 Mar 4;16(1):2174. PMID: 40038284 -
Nat Commun
Spatiotemporal control of neutrophil fate to tune inflammation and repair for myocardial infarction therapy. [Abstract]2024 Oct 1;15(1):8481. PMID: 39353987 -
Cell Death Differ
RPS23RG1 modulates tau phosphorylation and axon outgrowth through regulating p35 proteasomal degradation. [Abstract]2021 Jan;28(1):337-348. PMID: 32908202 -
Transl Neurodegener
Neuronal double-stranded DNA accumulation induced by DNase II deficiency drives tau phosphorylation and neurodegeneration. [Abstract]2024 Aug 2;13(1):39. PMID: 39095921 -
Acta Pharm Sin B
Gestational dexamethasone exposure impacts hippocampal excitatory synaptic transmission and learning and memory function with transgenerational effects. [Abstract]2023 Sep;13(9):3708-3727. PMID: 37719378 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Small
Self-Assembled PD-L1 Downregulator to Boost Photodynamic Activated Tumor Immunotherapy Through CDK5 Inhibition. [Abstract]2024 Jun 10:e2311507. PMID: 38856024 -
Redox Biol
BPTF inhibition antagonizes colorectal cancer progression by transcriptionally inactivating Cdc25A. [Abstract]2022 Sep:55:102418. PMID: 35932692 -
Clin Cancer Res
CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma. [Abstract]2024 Sep 13;30(18):4179-4189. PMID: 39052240 -
EMBO Mol Med
ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer. [Abstract]2024 Oct;16(10):2402-2426. PMID: 39271958 -
Cell Syst
A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]2018 Apr 25;6(4):424-443.e7. PMID: 29655704 -
Neoplasia
Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. [Abstract]2018 Mar 28;20(5):478-488. PMID: 29605721 -
Oncogene
DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma. [Abstract]2026 Jun 10. PMID: 42270776 -
Cell Rep
2021 Jul 20;36(3):109394. PMID: 34289372 -
Br J Cancer
Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT. [Abstract]2023 Mar;128(7):1344-1359. PMID: 36717670 -
J Med Chem
Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration. [Abstract]2021 Mar 11;64(5):2725-2738. PMID: 33619967 -
J Pineal Res
Melatonin Enhances Aquaporin 4 and Alpha-Syntrophin Interaction by Inhibiting Cyclin-Dependent Kinase 5 Activity to Preserve Glymphatic Function in Neonatal Hypoxic-Ischemic Encephalopathy. [Abstract]2025 Jul;77(4):e70063. PMID: 40506855 -
Eur J Pharmacol
Cyclin-dependent kinase 5 inhibitor attenuates lipopolysaccharide-induced neuroinflammation through metabolic reprogramming. [Abstract]2022 Aug 15:929:175118. PMID: 35787890 -
Mol Cancer Res
Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2. [Abstract]2020 Jan;18(1):91-104. PMID: 31649026
(R)-Roscovitine purchased from MedChemExpress. Usage Cited in: Mol Cancer Res. 2020 Jan;18(1):91-104. [Abstract]
EW8 cells were released from a thymidine double block in the presence of LY2603618 (1 μM), Roscovitine (10 μM), or the combination of LY2603618 and Roscovitine. Cellular lysates were collected for immunoblotting 4 h after release from the block.
-
J Biol Chem
Selective PPARγ modulator Diosmin improves insulin sensitivity and promotes browning of white fat. [Abstract]2023 Apr;299(4):103059. PMID: 36841479 -
Oncol Rep
The cyclin‑dependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma. [Abstract]2020 Jan;43(1):306-317. PMID: 31746435 -
J Virol
2023 Jun 29;97(6):e0037023. PMID: 37219458
(R)-Roscovitine purchased from MedChemExpress. Usage Cited in: J Virol. 2023 Jun 29;97(6):e0037023. [Abstract]
Cell cycle distribution of T24 and UMUC-3 cells was analyzed 48 h posttreatment with 10 mM nutlin-3a, 10 mM LEE011, 1 mM CI-1040, and 10 mM roscovitine. Then, 24 h posttreatment, cells were infected with 100 MOI dl70-3. After further 24-h cultivation, cells were fixed, PI stained, and FACS analyzed using a BD FACS Calibur Flow Cytometry System.
(R)-Roscovitine purchased from MedChemExpress. Usage Cited in: J Virol. 2023 Jun 29;97(6):e0037023. [Abstract]
The levels of Rb and pRb expression were analyzed using immunoblotting in T24, UMUC-3, and A549 cells after 24-h treatment with the indicated concentrations of nutlin-3a, CI 1040, LEE011, and roscovitine.
(R)-Roscovitine purchased from MedChemExpress. Usage Cited in: J Virol. 2023 Jun 29;97(6):e0037023. [Abstract]
Roscovitine (10 μM; 48 h). Visualization and GFP expression analyses were performed in UMUC-3 cells 48 hours postinfection with E1-GFP/RGD with and without 10 mM LEE011.
-
Brain Res Bull
The effects of prolyl hydroxylase inhibition during and post, hypoxia, oxygen glucose deprivation and oxidative stress, in isolated rat hippocampal slices. [Abstract]2023 Dec:205:110822. PMID: 37984622 -
Biochimie
Inactivated AMPK-α2 promotes the progression of diabetic brain damage by Cdk5 phosphorylation at Thr485 site. [Abstract]2020 Jan;168:277-284. PMID: 31786229 -
Virology
Live cell, image-based high-throughput screen to quantitate p53 stabilization and viability in human papillomavirus positive cancer cells. [Abstract]2021 Aug:560:96-109. PMID: 34051479 -
-
-
Neuroreport
Golgi fragmentation induced by overactivated cyclin-dependent kinase 5 is associated with isoflurane-induced neurotoxicity. [Abstract]2018 Mar 7;29(4):241-246. PMID: 29227343
(R)-Roscovitine purchased from MedChemExpress. Usage Cited in: Neuroreport. 2018 Mar 7;29(4):241-246. [Abstract]
R-E 235da1 exposure increases Cdk5 activity. Protein expression levels of P-histone H1 and Cdk5. P-histone H1 levels represent the activity of Cdk5. Bands for Cdk5 are the input. R-E 235da1 exposure increased Cdk5 activity.
-
-
bioRxiv
2024 Nov 4:2024.10.08.617155. PMID: 39415993 -
-
-
Solvent & Solubility
DMSO : ≥ 100 mg/mL (282.13 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Rat kidney tubular epithelial cells (NRK52E) are used. CDK5 inhibitor (R)-Roscovitine (Seliciclib) (Ros.; 10 μM) and activator p35 (15 μM), PPARγ agonist BRL 49653 (Rosi.; 50 nM), and ERK1/2 inhibitor U0126 (50 nM) are used to treat NRK52E cells. Cells in each group are treated for 72 hours and then harvested for further analyses[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats[2]
Male Sprague Dawley rats (6-8 weeks of age) are given intraperitoneally a single injection of either Streptozotocin (65 mg/kg) diluted in 0.1 M citrate buffer pH 4.5 (diabetic) or citrate buffer (non-diabetic). Plasma glucose concentrations are determined using the glucose oxidase method on a glucose analyzer three days after the injection. Rats with a glucose level over 16.7 mM are considered diabetic and thus included in the study. Plasma glucose level is measured once every week. To investigate the effect of CDK5 inhibition on renal tubulointerstitial fibrosis, Seliciclib (25 mg/kg) is injected peritoneally to diabetic rats every day till sacrifice. DMSO is included as controls.
Mice[3]
Exponentially growing UMSCC47 cells are injected subcutaneously into the sacral area of female NUDE mice. Each mouse is inoculated with 2×105 cells in 50% matrigel and 50% PBS at a volume of 100 μL. After tumors reach a measurable size, the mice are given 16.5 mg/kg doses of intraperitoneal Seliciclib or vehicle injections. Body weight, tumor growth, and general behavior are monitored. Tumor volumes are measured every 3 days. Mice are sacrificed when the tumor exceeded a size of 0.5cm3.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Meijer L, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997 Jan 15;243(1-2):527-36. [Content Brief]
[2]. Bai X, et al. CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via erk1/2/pparγ pathway. Oncotarget. 2016 Apr 27. [Content Brief]
[3]. Gary C, et al. Selective antitumor activity of roscovitine in head and neck cancer. Oncotarget. 2016 May 23. [Content Brief]
[4]. Menn B, et al. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One. 2010 Aug 12;5(8):e12117. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8213 mL | 14.1064 mL | 28.2127 mL | 70.5318 mL |
| 5 mM | 0.5643 mL | 2.8213 mL | 5.6425 mL | 14.1064 mL | |
| 10 mM | 0.2821 mL | 1.4106 mL | 2.8213 mL | 7.0532 mL | |
| 15 mM | 0.1881 mL | 0.9404 mL | 1.8808 mL | 4.7021 mL | |
| 20 mM | 0.1411 mL | 0.7053 mL | 1.4106 mL | 3.5266 mL | |
| 25 mM | 0.1129 mL | 0.5643 mL | 1.1285 mL | 2.8213 mL | |
| 30 mM | 0.0940 mL | 0.4702 mL | 0.9404 mL | 2.3511 mL | |
| 40 mM | 0.0705 mL | 0.3527 mL | 0.7053 mL | 1.7633 mL | |
| 50 mM | 0.0564 mL | 0.2821 mL | 0.5643 mL | 1.4106 mL | |
| 60 mM | 0.0470 mL | 0.2351 mL | 0.4702 mL | 1.1755 mL | |
| 80 mM | 0.0353 mL | 0.1763 mL | 0.3527 mL | 0.8816 mL | |
| 100 mM | 0.0282 mL | 0.1411 mL | 0.2821 mL | 0.7053 mL |